论文部分内容阅读
目的探讨恩替卡韦联合复方鳖甲软肝片治疗乙肝肝硬化的临床疗效。方法选取宝鸡市陈仓医院2013年2—5月收治的乙肝肝硬化患者198例,随机分为对照组(n=100)和研究组(n=98)。对照组患者给予恩替卡韦治疗,研究组患者在对照组基础上给予复方鳖甲软肝片治疗,两组患者均持续治疗6个月。比较两组患者治疗前后乙肝病毒(HBV)血清学标记物[乙型肝炎e抗原(HBe Ag)、乙型肝炎e抗体(抗-HBe)]、乙肝病毒脱氧核糖核酸(HBV-DNA)及丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)水平,并比较两组患者不良反应发生情况。结果治疗前,两组患者HBe Ag阳性率、抗-HBe阳性率及HBV-DNA水平比较,差异无统计学意义(P>0.05);治疗后,研究组患者HBe Ag阳性率、HBV-DNA水平低于对照组,抗-HBe阳性率高于对照组(P<0.05)。治疗前,两组患者ALT、AST水平比较,差异无统计学意义(P>0.05);治疗后,研究组患者ALT、AST水平低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论恩替卡韦联合复方鳖甲软肝片治疗乙肝肝硬化的临床疗效确切,可有效提高机体免疫功能,降低HBV-DNA、ALT、AST水平,且安全性好。
Objective To investigate the clinical efficacy of entecavir combined with Biejia Ruangan Tablet in the treatment of hepatitis B cirrhosis. Methods A total of 198 patients with hepatitis B cirrhosis admitted in Chencang Hospital from February 2013 to May 2013 were randomly divided into control group (n = 100) and study group (n = 98). Patients in the control group were treated with entecavir. Patients in the study group were given Fufang Biejia Ruangan Pian on the basis of the control group, and both groups were treated for 6 months. Serum markers of hepatitis B virus (HBe Ag, hepatitis B e antibody (anti-HBe)], hepatitis B virus DNA (HBV-DNA) and hepatitis C virus (HBV) were compared between two groups before and after treatment Aminotransferase (ALT), aspartate aminotransferase (AST) levels, and compared the incidence of adverse reactions in both groups. Results Before treatment, the HBe Ag positive rate, anti-HBe positive rate and HBV-DNA level in the two groups had no significant difference (P> 0.05). After treatment, the positive rate of HBeAg and HBV-DNA level Lower than the control group, anti-HBe positive rate was higher than the control group (P <0.05). Before treatment, there was no significant difference in ALT and AST levels between the two groups (P> 0.05). After treatment, ALT and AST levels in study group were lower than those in control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion The clinical efficacy of entecavir and Fufang Biejia Ruangan Tablet in the treatment of hepatitis B cirrhosis is accurate, which can effectively improve the immune function, reduce the levels of HBV DNA, ALT and AST and have good safety.